person · Reporting owner

BATE KENNETH

Disclosed activity across 6 companies

Tapewire entity: 68889
SEC CIK: 0001210238

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635	Director	July 01, 2021	July 02, 2021
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	Director	November 05, 2025	November 07, 2025
Vanda Pharmaceuticals Inc.VNDA · Entity 5861	Director	June 15, 2017	June 19, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GENOCEA BIOSCIENCES, INC.

Report date July 01, 2021 · Filed July 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01	Direct	15,000	Reported balance After 2021-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.

MADRIGAL PHARMACEUTICALS, INC.

Report date November 05, 2025 · Filed November 07, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,627	Ending reported balance After 2025-11-05 transaction · row 14 14 source rows · reconciled sequence Row 1 · 2025-11-05 · Exercise / conversion · Acquired 5,470 · Balance 8,097 Row 2 · 2025-11-05 · Exercise / conversion · Acquired 10,000 · Balance 18,097 Row 3 · 2025-11-05 · Exercise / conversion · Acquired 1,105 · Balance 19,202 Row 4 · 2025-11-05 · Sale · Disposed 1,763 · Balance 17,439 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 5 · 2025-11-05 · Sale · Disposed 3,259 · Balance 14,180 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive. Row 6 · 2025-11-05 · Sale · Disposed 1,284 · Balance 12,896 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive. Row 7 · 2025-11-05 · Sale · Disposed 2,069 · Balance 10,827 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive. Row 8 · 2025-11-05 · Sale · Disposed 1,931 · Balance 8,896 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive. Row 9 · 2025-11-05 · Sale · Disposed 1,008 · Balance 7,888 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive. Row 10 · 2025-11-05 · Sale · Disposed 827 · Balance 7,061 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive. Row 11 · 2025-11-05 · Sale · Disposed 2,775 · Balance 4,286 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive. Row 12 · 2025-11-05 · Sale · Disposed 696 · Balance 3,590 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive. Row 13 · 2025-11-05 · Sale · Disposed 933 · Balance 2,657 F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive. Row 14 · 2025-11-05 · Sale · Disposed 30 · Balance 2,627 F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.45 · Expires 2026-07-22	Direct	0	Reported balance After 2025-11-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-11-05 · Exercise / conversion · Disposed 5,470 · Balance 0 F12: The shares underlying this option are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $303.79 · Expires 2028-06-19	Direct	0	Reported balance After 2025-11-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2025-11-05 · Exercise / conversion · Disposed 10,000 · Balance 0 F12: The shares underlying this option are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $280.04 · Expires 2031-06-25	Direct	0	Reported balance After 2025-11-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2025-11-05 · Exercise / conversion · Disposed 1,105 · Balance 0 F12: The shares underlying this option are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.

F12: The shares underlying this option are fully vested and exercisable.

Vanda Pharmaceuticals Inc.

Report date June 15, 2017 · Filed June 19, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,000	Reported balance After 2017-06-15 transaction · row 1 1 source row Row 1 · 2017-06-15 · Grant · Acquired 5,000 · Balance 5,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.75 · Expires 2027-06-14	Direct	10,000	Reported balance After 2017-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-15 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEO PHARMACEUTICALS, INC.

Report date January 19, 2023 · Filed January 19, 2023

Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	375	Reported balance After 2023-01-19 transaction · row 1 1 source row Row 1 · 2023-01-19 · Disposition to issuer · Disposed 375 · Balance 375 F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.90 · Expires 2023-05-29	Direct	0	Reported balance After 2023-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-19 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2024-06-19	Direct	0	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.10 · Expires 2025-04-02	Direct	0	Reported balance After 2023-01-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-19 · Disposition to issuer · Disposed 2,515 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2025-05-28	Direct	0	Reported balance After 2023-01-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-01-19 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2026-05-26	Direct	0	Reported balance After 2023-01-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-01-19 · Disposition to issuer · Disposed 6,402 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2027-06-21	Direct	0	Reported balance After 2023-01-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-01-19 · Disposition to issuer · Disposed 7,785 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.70 · Expires 2028-06-17	Direct	0	Reported balance After 2023-01-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2029-06-11	Direct	0	Reported balance After 2023-01-19 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2030-06-09	Direct	0	Reported balance After 2023-01-19 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2031-06-08	Direct	0	Reported balance After 2023-01-19 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-06	Direct	0	Reported balance After 2023-01-19 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-01-19 · Disposition to issuer · Disposed 22,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.

F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.

Astria Therapeutics, Inc.

Report date January 23, 2026 · Filed January 23, 2026

Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24	Direct	Reported balance After 2026-01-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-23 · Disposition to issuer · Disposed 16,666 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00	Direct	Reported balance After 2026-01-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-23 · Disposition to issuer · Disposed 8,333 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35	Direct	Reported balance After 2026-01-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18	Direct	Reported balance After 2026-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79	Direct	Reported balance After 2026-01-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-23 · Disposition to issuer · Disposed 26,550 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

Filing footnotes · ownership attribution and instrument terms

F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

Epizyme, Inc.

Report date August 12, 2022 · Filed August 16, 2022

Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-08-12 · Disposition to issuer · Disposed 8,060 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2024 Filed Jun 6, 2024 16:05 UTC	Astria Therapeutics, Inc. ATXS · Entity 68888	GrantStock Option (Right to Buy) · Derivative	14,100	$0.00 Strike: $9.18	$0.00	Disclosure SEC source: 0001104659-24-069065 · tm2416582-1_4seq1.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	11,212	$0.00 Strike: $105.08	$0.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · derivative · entry 25 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,212 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	7	$249.05	$1,743.35	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 21 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	193	$248.49	$47,958.32	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 20 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,205 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.01 to $249.00, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	100	$246.88	$24,688.05	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 19 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,398 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.87 to $246.95, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	567	$246.20	$139,596.99	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 18 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,498 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.77 to $246.35, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	2,080	$244.97	$509,527.20	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 17 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,065 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.73 to $245.52, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	7,048	$244.27	$1,721,630.47	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 16 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,145 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.73 to $244.71, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,217	$243.28	$296,074.56	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 15 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,193 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.59 to $243.54, inclusive. Read SEC document
April 02, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	11,212	$105.08	$1,178,156.96	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 14 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	1,277	$0.00 Strike: $105.08	$0.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · derivative · entry 24 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,212 Underlying: Common Stock · 1,277 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $100.45	$0.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · derivative · entry 23 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $9.45	$0.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · derivative · entry 22 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	274	$266.91	$73,132.02	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 13 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.73 to $267.21, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	700	$265.36	$185,748.99	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 12 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.04 to $265.64, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	116	$264.73	$30,709.18	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 11 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,172 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.00 to $264.85, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	143	$263.08	$37,620.67	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 10 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,288 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.00 to $263.98, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	841	$262.18	$220,493.13	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 9 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,431 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.95 to $262.82, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	200	$259.13	$51,826.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 8 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,272 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.11 to $259.15, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	2,104	$258.24	$543,339.48	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 7 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,472 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.02 to $258.93, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	2,790	$257.33	$717,940.10	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 6 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,576 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.01 to $258.00, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	7,411	$256.49	$1,900,850.35	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 5 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,366 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.01 to $256.99, inclusive. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	6,698	$255.62	$1,712,119.32	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 4 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,777 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.01 to $256.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	1,277	$105.08	$134,187.16	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 3 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	10,000	$100.45	$1,004,500.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2024 Filed Apr 4, 2024 00:44 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	10,000	$9.45	$94,500.00	Disclosure SEC source: 0000899243-24-000245 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2023 Filed Jun 20, 2023 22:41 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	1,198	$0.00	$0.00	Disclosure SEC source: 0000899243-23-016056 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,198 F1 · kind: Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document
June 02, 2023 Filed Jun 6, 2023 08:00 UTC	Astria Therapeutics, Inc. ATXS · Entity 68888	GrantStock Option (Right to Buy) · Derivative	14,100	$0.00 Strike: $11.35	$0.00	Disclosure SEC source: 0001104659-23-068334 · tm2317752-1_4seq1.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2033-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	22,500	Not disclosed Strike: $4.27	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 12 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2032-06-06 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	12,500	Not disclosed Strike: $7.27	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 11 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-06-08 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	Not disclosed Strike: $7.52	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 10 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2030-06-09 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	Not disclosed Strike: $7.60	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 9 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2029-06-11 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	4,000	Not disclosed Strike: $22.70	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 8 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-06-17 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	7,785	Not disclosed Strike: $7.00	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 7 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,785 shares Expires 2027-06-21 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	6,402	Not disclosed Strike: $9.20	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 6 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,402 shares Expires 2026-05-26 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	2,000	Not disclosed Strike: $20.00	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 5 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2025-05-28 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	2,515	Not disclosed Strike: $16.10	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 4 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,515 shares Expires 2025-04-02 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	1,250	Not disclosed Strike: $15.70	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 3 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2024-06-19 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerStock Option (Right to Buy) · Derivative	1,250	Not disclosed Strike: $25.90	Not disclosed	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · derivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2023-05-29 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document
January 19, 2023 Filed Jan 19, 2023 17:19 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	Disposition to issuerCommon Stock	375	$15.00	$5,625.00	Disclosure SEC source: 0000899243-23-002195 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 F1 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. Read SEC document
August 12, 2022 Filed Aug 16, 2022 18:55 UTC	Epizyme, Inc. EPZM · Entity 12703	Disposition to issuerCommon Stock, par value $0.0001	8,994	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-028858 · doc4.xml · nonDerivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. F2 · price: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. Read SEC document
August 12, 2022 Filed Aug 16, 2022 18:55 UTC	Epizyme, Inc. EPZM · Entity 12703	Disposition to issuerCommon Stock, par value $0.0001	8,060	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-028858 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,994 F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Read SEC document
June 16, 2022 Filed Jun 21, 2022 10:30 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	9,470	$0.00 Strike: $65.06	$0.00	Disclosure SEC source: 0000899243-22-023234 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document
June 09, 2022 Filed Jun 9, 2022 18:00 UTC	Astria Therapeutics, Inc. ATXS · Entity 68888	GrantStock Option (right to buy) · Derivative	8,333	$0.00 Strike: $2.99	$0.00	Disclosure SEC source: 0001104659-22-069759 · tm2218033-6_4seq1.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document
June 09, 2022 Filed Jun 21, 2022 08:33 UTC Amendment	Astria Therapeutics, Inc. ATXS · Entity 68888	GrantStock Option (right to buy) · Derivative	8,333	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001104659-22-072753 · tm2218796-6_4aseq1.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2032-06-08 F1 · derivative.exercise_price: This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported. F2 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document
June 07, 2022 Filed Jun 8, 2022 16:58 UTC	AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602	GrantStock Option (right to buy) · Derivative	22,500	$0.00 Strike: $4.27	$0.00	Disclosure SEC source: 0001628280-22-016604 · wf-form4_165472191761209.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments beginning July 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document
May 17, 2022 Filed May 19, 2022 16:30 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantStock Option (Right to Buy) · Derivative	41,006	$0.00 Strike: $0.56	$0.00	Disclosure SEC source: 0000899243-22-018843 · doc4.xml · derivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,006 Underlying: Common Stock · 41,006 shares Expires 2032-05-16 F2 · derivative.exercise_date: This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document
May 17, 2022 Filed May 19, 2022 16:30 UTC	Epizyme, Inc. EPZM · Entity 12703	GrantCommon Stock, par value $0.0001	8,994	$0.00	$0.00	Disclosure SEC source: 0000899243-22-018843 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,054 F1 · shares: Consists of shares of Common Stock issuable under 8,994 restricted stock units ("RSUs") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document
July 01, 2021 Filed Jul 2, 2021 11:54 UTC	GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0001457612-21-000080 · wf-form4_162524122536579.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 100% of the options are scheduled to vest on the first anniversary of the grant date. Read SEC document
June 17, 2021 Filed Jun 21, 2021 12:02 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	12,489	$0.00 Strike: $105.08	$0.00	Disclosure SEC source: 0000899243-21-024665 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.